ArticleLancet (London, England)2021
Tocilizumab in COVID-19: some clarity amid controversy.
Article in Lancet (London, England), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- IL-6 Inhibits Invasion in a Murine Model of Endometriosis.Reproductive sciences (Thousand Oaks, Calif.) · 2025Article
- Loss of neutrophil Shp1 produces hemorrhagic and lethal acute lung injury.bioRxiv : the preprint server for biology · 2024Article
- Future applications of host direct therapies for infectious disease treatment.Frontiers in immunology · 2024Review
- Epigenetic perspectives associated with COVID-19 infection and related cytokine storm: an updated review.Infection · 2023Review
- Neurologic sequelae of COVID-19 are determined by immunologic imprinting from previous coronaviruses.Brain : a journal of neurology · 2023Article
- COVID-19 Therapeutics and Considerations for Pregnancy.Obstetrics and gynecology clinics of North America · 2023Review
- Severe COVID-19 and non-COVID-19 severe sepsis converge transcriptionally after a week in the intensive care unit, indicating common disease mechanisms.Frontiers in immunology · 2023Observational
- Persistence is key: unresolved immune dysfunction is lethal in both COVID-19 and non-COVID-19 sepsis.Frontiers in immunology · 2023Article
- A review of clinical efficacy data supporting emergency use authorization for COVID-19 therapeutics and lessons for future pandemics.Clinical and translational science · 2022Review
- Review
- Allocated but not treated: the silent 16.Lancet (London, England) · 2022Article
- Tocilizumab in patients hospitalised with COVID-19 pneumonia: Efficacy, safety, viral clearance, and antibody response from a randomised controlled trial (COVACTA).EClinicalMedicine · 2022Article
- C-reactive protein cut-off for early tocilizumab and dexamethasone prescription in hospitalized patients with COVID-19.Scientific reports · 2022Article
- Anakinra in COVID-19: A step closer to the cure.European journal of internal medicine · 2022Article
- I've looked at gut from both sides now: Gastrointestinal tract involvement in the pathogenesis of SARS-CoV-2 and HIV/SIV infections.Frontiers in immunology · 2022Review
- Immune-Mediated Mechanisms of COVID-19 Neuropathology.Frontiers in neurology · 2022Review
- Clonal Wars: Monoclonal Antibodies Against Infectious Pathogens.DNA and cell biology · 2022Article
- Darunavir ethanolate: Repurposing an anti-HIV drug in COVID-19 treatment.European journal of medicinal chemistry reports · 2021Review
- Vaccination against SARS-CoV-2 in Patients with Inflammatory Bowel Diseases: Where Do We Stand?Life (Basel, Switzerland) · 2021Review
- COVID-19 Therapeutics for Low- and Middle-Income Countries: A Review of Candidate Agents with Potential for Near-Term Use and Impact.The American journal of tropical medicine and hygiene · 2021Review
Corrections and comments
- Commented on by
- Comment on
Authors and funding
2 authors.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.